PitchSend

Investor Presentaiton

B-cell function Investor presentation Full year 2018 Slide 46 Insulin is the ultimate care for people with diabetes Progression of type 2 diabetes and treatment intensification Distribution of patients and value across treatment classes Diet and exercise OAD: Oral anti-diabetic changing diabetes Time OAD GLP-1 Insulin GLP-1 SGLT-2 DPP-IV Other OADs 100% 6% 20% OAD 80% 37% 51% OAD 11% 60% 68% 14% 12% 40% Insulin 5,0% 48% 20% 26% 0% Patients Value Note: Patient distribution across treatment classes is indicative and based on data for the USA, the UK, Germany and France. Value figures based on IQVIA MAT Nov, 2018 Source: IQVIA PharMetrix claims data, IQVIA disease analyser, IQVIA MIDAS Other OADs covers: Metformin, SU, TZDs Numbers do not add up to 100% due to rounding novo nordisk

View entire presentation